MA39337B1 - Modulateurs de pyrazines de gpr6 - Google Patents

Modulateurs de pyrazines de gpr6

Info

Publication number
MA39337B1
MA39337B1 MA39337A MA39337A MA39337B1 MA 39337 B1 MA39337 B1 MA 39337B1 MA 39337 A MA39337 A MA 39337A MA 39337 A MA39337 A MA 39337A MA 39337 B1 MA39337 B1 MA 39337B1
Authority
MA
Morocco
Prior art keywords
gpr6
modulators
pyrazine
compounds
methods
Prior art date
Application number
MA39337A
Other languages
English (en)
Other versions
MA39337A1 (fr
Inventor
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Huikai Sun
Shota Kikuchi
Maria Hopkins
Mark E Adams
Jason W Brown
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39337A1 publication Critical patent/MA39337A1/fr
Publication of MA39337B1 publication Critical patent/MA39337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des composés de formule (i) : qui sont utiles en tant que modulateurs de gpr6, des compositions pharmaceutiques de ceux-ci, des méthodes pour le traitement de conditions associées à gpr6, des procédés de fabrication de ces composés et des intermédiaires de ceux-ci.
MA39337A 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6 MA39337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14
PCT/US2015/015841 WO2015123533A1 (fr) 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6

Publications (2)

Publication Number Publication Date
MA39337A1 MA39337A1 (fr) 2017-10-31
MA39337B1 true MA39337B1 (fr) 2019-11-29

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39337A MA39337B1 (fr) 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (fr)
EP (1) EP3105216B1 (fr)
JP (1) JP6484640B2 (fr)
KR (1) KR20160122215A (fr)
CN (1) CN106103421B (fr)
AU (1) AU2015218402B2 (fr)
BR (1) BR112016018418A2 (fr)
CA (1) CA2939382A1 (fr)
CL (1) CL2016002043A1 (fr)
CR (1) CR20160428A (fr)
DO (1) DOP2016000211A (fr)
EA (1) EA033861B1 (fr)
EC (1) ECSP16074207A (fr)
ES (1) ES2702205T3 (fr)
GE (2) GEP20186893B (fr)
IL (1) IL247140B (fr)
MA (1) MA39337B1 (fr)
MX (1) MX369857B (fr)
MY (1) MY184366A (fr)
PE (1) PE20170245A1 (fr)
PH (1) PH12016501613B1 (fr)
UA (1) UA117779C2 (fr)
WO (1) WO2015123533A1 (fr)
ZA (1) ZA201606077B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105216B1 (fr) * 2014-02-14 2018-10-10 Takeda Pharmaceutical Company Limited Modulateurs pyraziniques de gpr6
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2018172984A1 (fr) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
CA3054945A1 (fr) * 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Carboxamides heteroaromatiques substitues par piperidinyle et piperazinyle en tant que modulateurs de gpr6
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
JP2023527961A (ja) * 2020-04-30 2023-07-03 オレゴン ヘルス アンド サイエンス ユニヴァーシティ ｇｐｒ３９タンパク質のアンタゴニスト

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
CN1364167A (zh) * 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
CN1231473C (zh) 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪
DK1397351T3 (da) * 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
WO2004054617A1 (fr) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. Agents prophylactiques et/ou agents therapeutiques pour maladies du systeme nerveux central
US7456180B2 (en) 2003-07-30 2008-11-25 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP2007524682A (ja) 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
EP1742935B1 (fr) 2004-04-13 2010-02-24 Icagen, Inc. Pyrazines polycycliques tenant lieu de modulateurs du canal ionique du potassium
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
JP2008540575A (ja) 2005-05-13 2008-11-20 レキシコン・ファーマシューティカルズ・インコーポレーテッド 多環系化合物とその使用の方法
WO2007044085A2 (fr) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
NZ603876A (en) * 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
EP2771069A4 (fr) * 2011-10-27 2015-08-26 Mayo Foundation Inhibition de polypeptides de récepteurs 6 kinases couplés à une protéine g
JP6193374B2 (ja) * 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
KR20160063366A (ko) 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
EP3105216B1 (fr) * 2014-02-14 2018-10-10 Takeda Pharmaceutical Company Limited Modulateurs pyraziniques de gpr6

Also Published As

Publication number Publication date
CN106103421B (zh) 2019-04-09
MX2016010529A (es) 2016-10-31
MY184366A (en) 2021-04-01
AU2015218402B2 (en) 2019-07-11
BR112016018418A2 (pt) 2017-08-08
ZA201606077B (en) 2018-11-28
MX369857B (es) 2019-11-25
US20170174659A1 (en) 2017-06-22
PE20170245A1 (es) 2017-03-30
JP2017509601A (ja) 2017-04-06
AU2015218402A1 (en) 2016-09-15
WO2015123533A1 (fr) 2015-08-20
GEAP201814266A (en) 2018-05-10
UA117779C2 (uk) 2018-09-25
PH12016501613A1 (en) 2017-02-06
CL2016002043A1 (es) 2017-02-17
JP6484640B2 (ja) 2019-03-13
GEP20186893B (en) 2018-09-10
EP3105216A1 (fr) 2016-12-21
US10273225B2 (en) 2019-04-30
ECSP16074207A (es) 2017-09-29
CR20160428A (es) 2017-04-04
EP3105216B1 (fr) 2018-10-10
KR20160122215A (ko) 2016-10-21
MA39337A1 (fr) 2017-10-31
IL247140A0 (en) 2016-09-29
CN106103421A (zh) 2016-11-09
PH12016501613B1 (en) 2021-10-01
CA2939382A1 (fr) 2015-08-20
US20180258073A1 (en) 2018-09-13
DOP2016000211A (es) 2016-10-16
ES2702205T3 (es) 2019-02-27
EA201691632A1 (ru) 2017-02-28
EA033861B1 (ru) 2019-12-03
IL247140B (en) 2020-02-27
US10000468B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
EA201790806A1 (ru) Иммунорегулирующие средства
CO2017005218A2 (es) Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden los compuestos”
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CO2017005452A2 (es) Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden tales compuestos
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
JOP20170169A1 (ar) مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
BR112016028255A2 (pt) agentes imunorreguladores
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
EA201691514A1 (ru) Соединения
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201790570A1 (ru) Модуляторы р2х7
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MX2018016290A (es) Agente antidesgaste.
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
EA202090107A3 (ru) Композиции, содержащие бактериальные штаммы